CAR-T

13 April 2026

Clinical trial in Zaragoza: a live cancer drug will be manufactured in a special room at the Servet Hospital for a single patient

A new CAR-T therapy for rare cancers, developed by researchers in Aragon, reprograms each person's immune cells to attack the tumor.
2 March, 2026

A breakthrough from Aragon opens new avenues of immunotherapy for rare blood diseases

A preclinical study by the IIS Aragón demonstrates, for the first time, the viability of a CAR-T therapy aimed at myeloproliferative neoplasms (rare blood diseases with limited therapeutic options).